Table 2.

Number of cases (n) and SIRs of selected second cancers after esophageal cancer by histologic type of esophageal cancer

Site of the second cancer (ICD-9)Adenocarcinoma
SCC
nSIR (95% CI)nSIR (95% CI)
All malignant (140-208)1971.14 (0.99-1.32)6041.28 (1.18-1.38)
    Oral cavity, pharynx (140-149)71.70 (0.68-3.50)856.68 (5.33-8.26)
        Lip (140)32.52 (0.52-7.36)61.68 (0.62-3.66)
        Tongue (141)11.63 (0.04-9.10)189.98 (5.91-15.8)
        Salivary gland (142)13.18 (0.08-17.7)11.08 (0.03-6.00)
        Mouth (143-145)22.19 (0.26-7.90)249.49 (6.08-14.1)
        Pharynx (146-149)00.00 (0.00-3.40)369.23 (6.47-12.8)
            Oropharynx (146)00.00 (0.00-8.77)1411.6 (6.35-19.5)
            Nasopharynx (147)00.00 (0.00-21.4)21.47 (0.18-5.30)
            Hypopharynx (148)00.00 (0.00-9.52)1412.6 (6.87-21.1)
            Pharynx, unspecified (149)00.00 (0.00-34.8)627.7 (10.2-60.3)
    Stomach (151)182.13 (1.26-3.37)511.53 (1.14-2.01)
    Liver (155) (−155.2)00.00 (0.00-2.27)131.79 (0.95-3.06)
    Larynx (161)20.98 (0.12-3.53)173.24 (1.88-5.18)
    Lung (162)270.91 (0.60-1.32)1121.55 (1.28-1.87)
    Female breast (174)61.03 (0.38-2.25)310.84 (0.57-1.20)
    Cervix uteri (180)00.00 (0.00-6.41)51.21 (0.39-2.83)
    Prostate (185)421.36 (0.98-1.84)550.92 (0.69-1.19)
    Testis (186)00.00 (0.00-17.0)12.52 (0.06-14.0)
    Bladder (188, 189.3, 189.4)70.68 (0.27-1.39)281.25 (0.83-1.81)
    Kidney (189) (-189.3, 189.4)61.46 (0.54-3.19)221.88 (1.18-2.85)
    Thyroid gland (193)24.04 (0.49-14.6)72.92 (1.18-6.02)
    Non–Hodgkin lymphoma (200, 202)81.82 (0.79-3.59)60.50 (0.18-1.09)
  • Abbreviation: SCC, squamous cell carcinoma.